Novel adjuvants & delivery vehicles for vaccines development: A road ahead

Indian Journal of Medical Research

Volumn 138, Issue NOV, 2013, Pages 779-795

  Mohan, Teena ^a   Verma, Priyanka ^a   Nageswara Rao, D ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Adjuvant; Antibody; Antigen; Epitope; ISCOMs; Liposomes; MHC; Microsphere; Peptide; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; CPG OLIGODEOXYNUCLEOTIDE; ENERGIN B; FREUND ADJUVANT; GARDOZIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS A VACCINE; INFLUENZA VACCINE; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; ISCOM; LIPOPEPTIDE; LIPOPOLYSACCHARIDE; MIFAMURTIDE; MONTANIDE ISA 51; MURAMYL DIPEPTIDE; NANOPARTICLE; PATTERN RECOGNITION RECEPTOR; PROTEASOME; PULLULAN; SAPONIN; SHIGA TOXIN; STAPHYLOCOCCUS ENTEROTOXIN; UNCLASSIFIED DRUG; VIROSOME; ADJUVANT 65; ALUMINUM SALT; CALCIUM PHOSPHATE; CARBOHYDRATE ADJUVANT; CHOLERA TOXIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CYTOKINE; IMMUNOLOGICAL ADJUVANT; LIPOSOME; MONTANIDE; PERTUSSIS TOXIN; QUIL A; UNINDEXED DRUG; VACCINE; VIRUS LIKE PARTICLE VACCINE; VIRUS VECTOR;

BIODEGRADABILITY; CPG ISLAND; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INNATE IMMUNITY; NANOEMULSION; REVIEW; VIRUS LIKE AGENT; ADJUVANT THERAPY; ANTIGEN PRESENTATION; B LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; DRUG RELEASE; DRUG TRANSPORT; EMULSION; HUMORAL IMMUNITY; MUCOSAL IMMUNITY; NONHUMAN; PARENTERAL DRUG ADMINISTRATION; TH1 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; IMMUNITY, HUMORAL; LIPOPOLYSACCHARIDES; LIPOSOMES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES;

EID: 84891692114     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Petrovsky N, Cooper PD. Carbohydrate-based immune adjuvants. Expert Rev Vaccines 2011; 10: 523-37.
2. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82: 488-96.
3. Rivas E, Gomez-Arnaiz M, Ricoy JR, Mateos F, Simón R, García-Peñas JJ, et al. Macrophagic myofasciitis in childhood: a controversial entity. Pediatr Neurol 2005; 33: 350-6.
4. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001; 124: 1821-31.
5. Holt LB. Quantitative studies in diphtheria prophylaxis; the primary response. Br J Exp Pathol 1949; 30: 289-97.
6. Freund J. The effect of paraffin oil and mycobacteria on antibody formation and sensitization; a review. Am J Clin Pathol 1951; 21: 645-56.
7. Kataoka K, Fujihashi K. Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines. Expert Rev Vaccines 2009; 8: 1183-93.
8. McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD, et al. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 2009; 206: 2967-76.
9. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine 2011; 29: 3341-55.
10. Cox JC, Coulter AR. Adjuvants-a classification and review of their modes of action. Vaccine 1997; 15: 248-56.
11. Degten WG, Jansen T, Schijns VE. Vaccine adjuvant technology: from mechanistic concepts to practical applications. Expert Rev Vaccines 2003; 2: 327-35.
12. Verthelji D, Klinman DM. Immunoregulatory activity of CpG oligonucleotides in human and non-human primates. Int Immunol 2003; 109: 64-71.
13. Seya T, Akazawa T, Vehori J, Matsumoto M, Azuma I, Toyoshima ZK. Role of toll-like receptors and their adapters in adjuvant immunotherapy for cancer. Anti Cancer Res 2003; 23: 4369-76.
14. Agarwal S, Agarwal A, Doughty B, Gertuitz A, Blenis J, Van Dyke T, et al. Different toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and C-Fos. Immunology 2003; 171: 4984-9.
15. Sasaki S, Takeshita F, Xin KQ, Ishiii N Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods 2003; 31: 243-54.
16. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008; 8: 235-47.
17. Podda A. The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19: 2673-80.
18. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. Plos One 2009; 4: e4384.
19. Boyle J, Eastman D, Millar C, Camuglia S, Cox J, Pearse M, et al. The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. Vaccine 2007; 25: 2541-4.
20. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Drame M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27: 6284-90.
21. Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006; 24: 20-6.
22. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, et al. Adjuvanted H5N1 vaccine induces early CD4+ T-cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009b; 106: 3877-82.
23. Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Drame M, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28: 849-57.
24. Vandepapeliere P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T-cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008; 26: 1375-86.
25. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009a; 106: 7962-7.
26. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010; 2: 15ra5.
27. Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007; 25: 763-75.
28. Malherbe L, Mark L, Fazilleau N, McHeyzer-Williams LJ, McHeyzer-Williams MG. Vaccine adjuvants alters TCR-based selection thresholds. Immunity 2008; 28: 698-709.
29. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004; 82: 497-505.
30. Byars NE, Allison AC. Immunologic adjuvants: general properties, advantages and limitations. Laboratory methods in Immunology, Boca Raton, CRC Press 1990; 39-51.
31. Edelman R. Vaccine Adjuvants. Res Infect Dis 1980; 2: 370-83.
32. Nentra MR, Pringault E Krachenbuhl JP. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Ann Rev Immunol 1996; 14: 275-300.
33. Goto N, Kato H, Mayeama JI, Eto K Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 1993; 11: 914-8.
34. He Q, Mitchell A, Morcol T, Bell SJD. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diagn Lab Immunol 2000; 9: 899-903.
35. Jiang D, Premchandra GS, Johnson C, Hem SL. Structure and adsorption properties of commercial calcium phosphate adjuvant. Vaccine 2004; 23: 693-8.
36. Jackson LR, Fox JG. Institutional policies and guidelines on adjuvants and antibody production. ILAR J 1995; 37: 141-50.
37. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin Exp Immunol 1980; 39: 435-41.
38. Freund J. The mode of action of immunologic adjuvants. Adv Tuberc Res 1956; 7: 130-48.
39. Dvorak HF, Dvorak AM, Simpson BA, Richerson HB, Leskowitz S, Karnovsky MJ. Cutaneous basophil hypersensitivity II: A light and electron microscopic description. J Exp Med 1970; 132: 558-82.
40. Dar P, Kalaivanan R, Sied N, Mamo B, Kishore S, Suryanarayana VV, et al. Montanide ISA™ 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle. Vaccine. 2013; 31: 3327-32.
41. Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 2003; 21: 4234-7.
42. Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 1996; 174: 1168-75.
43. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A. The adjuvants aluminium hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 2008; 180: 5402-12.
44. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010; 22: 411-6.
45. Lee JB, Jang JE, Song MK, Chang J. Intranasal delivery of cholera toxin induces Th17-dominated T-cell response to bystander antigens. PLoS One 2009; 4: e5190.
46. Orozco-Morales M, Sánchez-García FJ, Guevara-Salazar P, Arrieta O, Hernández-Pedro NY, Sánchez-García A, et al. Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin. J Cancer Res Clin Oncol 2012; 138: 23-33.
47. Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, et al. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses andtoxinA-neutralizing antibodies in mice. Infect Immun 2007; 75: 2826-32.
48. Gupta P, Singh MK, Singh Y, Gautam V, Kumar S, Kumar O, et al. RecombinantShiga toxinB subunit elicits protection againstShiga toxinvia mixed Th type immune response in mice. Vaccine 2011; 29: 8094-100.
49. Lowell GH, Kaminski RW, Grate S, Hunt RE, Charney C, Zimmer S, et al. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect Immun 1996; 64: 1706-13.
50. Qiu HN, Wong CK, Chu IM, Hu S, Lam CW. Muramyl dipeptide mediated activation of human bronchial epithelial cells interacting with basophils: a novel mechanism of airway inflammation. Clin Exp Immunol 2013; 172: 81-94.
51. Bessler WG, Baier W, Esche U, Hoffmann P, Heinevetter L, Wiesmüller KH, et al. Bacterial lipopeptides constitute efficient novel immunogens and adjuvants in parenteral and oral immunization. Behring Inst Mitt 1997; 98: 390-9.
52. Burt D, Mallett C, Plante M, Zimmermann J, Torossian K, Fries L. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations. Expert Rev Vaccines 2011; 10: 365-75.
53. Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, Nakagawa S, et al. Positively charged liposomes function as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Control Release 1999; 61: 233-40.
54. Katre NV. Liposome-based depot injection technologies; how versatile are they? Am J Drug Deliv 2004; 2: 213-27.
55. Ronnberg B, Fekadu M, Morien B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine 1995; 13: 1375-82.
56. Fossum C, Bergström M, Lövgren K, Watson DL, Morein B. Effect of ISCOMs and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: comparison of spleen cells from mice inoculated with iscoms and/or matrix. Cell Immunol 1990; 129: 414-25.
57. Sjolander S, Drave D, Davis R, Beezum L, Pearse M, Cox JC. Intranasal immunisation with influenza-ISCOMATRIX adjuvanted influenza vaccine. Vaccine 2003; 21: 946-9.
58. Rimmelzwann GF, Baars M, VanAmerongen G, VanBeek R, Oestrhaus AD. A single dose of an ISCOM influenza Vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect cynomologus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine 2001; 20: 158-63.
59. Mukherjee C, Mäkinen K, Savolainen J, Leino R. Chemistry and biology of oligovalent β-(1→2)-linked oligomannosides: New insights intocarbohydrate-based adjuvantsin immunotherapy. Chemistry 2013; 19: 7961-74.
60. Pun PB, Bhat AA, Mohan T, Kulkarni S, Paranjape R, Rao DN. Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN co-entrapped in microparticles enhances the mucosal and systemic immune responses. Int Immunopharmacol 2009; 9: 468-77.
61. Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011; 10: 499-511.
62. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol 2004; 22: 181-215.
63. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002; 23: 291-6.
64. Mohan T, Mitra D, Rao DN. Nasal delivery of PLG microparticle encapsulated defensin peptides adjuvanted gp41 antigen confers strong and long-lasting immunoprotective response against HIV-1. Immunol Res. In press 2013.
65. Mohan T, Sharma C, Bhat AA, Rao DN. Modulation of HIV peptide antigen specific cellular immune response by synthetic α-and β-defensin peptides. Vaccine 2013; 31: 1707-16.
66. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996; 183: 7-11.
67. Taylor CE. Cytokines as adjuvants for vaccines: antigen-specific responses differ from polyclonal responses. Infect Immun 1995; 63: 3241-4.
68. Nambiar JK, Ryan AA, Kong CU, Britton WJ, Triccas JA. Modulation of pulmonary DC function by vaccine encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection. Eur J Immunol 2010; 40: 153-61.
69. LeBon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type-I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in-vivo. Immunity 2001; 14: 461-70.
70. Staats HF, Ennis Jr FA. IL-1 is an effective adjuvant for mucosal and systemic immune responses when co-administered with protein immunogens. J Immunol 1999; 162: 6141-7.
71. Abraham E, Shah S. Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. J Immunol 1992; 49: 3719-26.
72. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arth Res Ther 2006; 8 (Suppl 2): S2.
73. Berḿudez-Humaŕan LG, Cortes-Perez NG, Lefevre F, Guimarães V, Rabot S, Alcocer-Gonzalez JM, et al. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005; 175: 7297-302.
74. Shanmugham LN, Petrarca C, Frydas S, Donelan J, Castellani ML, Boucher W, et al. IL-15 an immunoregulatory and anti-cancer cytokine: Recent advances. J Exp Clin Can Res 2006; 25: 529-36.
75. Eberl M, Beck E, Coulson PS, Okamura H, Wilson RA, Mountford AP. IL-18 potentiates the adjuvant properties of IL-12 in the induction of a strong Th1 type immune response against a recombinant antigen. Vaccine 2000; 18: 2002-8.
76. Huffnagle GB, Strieter RM, McNeil LK, McDonald RA, Burdick MD, Kunkel SL, et al. Macrophage inflammatory protein-1α (MIP-1α) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection. J Immunol 1997; 159: 318-27.
77. Manocha M, Pal PC, Chitralekha KT, Thomas BE, Tripathi V, Gupta SD, et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 2005; 23: 5599-617.
78. Malyala P, Singh M. Microparticle adjuvants: preparation and formulation with antigens. Meth Mol Biol 2010; 626: 91-101.
79. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010; 9: 1095-107.
80. Esparza I, Kissel T. Parameters affecting the immunogenicity of microencapsulated tetanus toxoid. Vaccine 1992; 10: 714-20.
81. Rakhmilevich AL, Imboden, Hao Z, Macklin MD, Robert T, Wright KM, et al. Effective particle-mediated vaccination against mouse melanoma by co-administration of plasmid DNA Encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 2001; 7: 952-61.
82. Kemp MM, Kumar A, Mousa S, Park TJ, Ajayan P, Kubotera N, et al. Synthesis ofgoldand silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities. Biomacromolecules 2009; 10: 589-95.
83. Jiang L, Li X, Liu L, Zhang Q. Cellular uptake mechanism and intracellular fate of hydrophobically modified pullulan nanoparticles. Int J Nanomed 2013; 8: 1825-34.
84. Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth AA, et al. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. Int J Cancer 2012; 130: 584-92.
85. Lövgren Bengtsson K, Morein B, Osterhaus AD. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines 2011; 10: 401-3.
86. Moser C, Amacker M, Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 2011; 10: 437-46.
87. De Bruijn IA, Nauta J, Gerez L, Palache AM. The virosomal influenza vaccineInvivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects. Vaccine 2006; 24: 6629-31.
88. Sominskaya I, Skrastina D, Dislers A, Vasiljev D, Mihailova M, Ose V, et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBVand HCV epitopes. Clin Vaccine Immunol 2010; 17: 1027-33.
89. Hernandez BY, Ton T, Shvetsov YB, Goodman MT, Zhu X. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies. Clin Vaccine Immunol 2012; 19: 1348-52.
90. Van Kampen KR, Zhang J, Foster JW, Chen DT, Marks D, Elmets CA, et al. Safety and immunogenicity of adenovirus vectored nasl and epicutaneous influenza vaccines in humans. Vaccine 2005; 23: 1029-36.
91. Cantazaro AT, Koup RA, Rodeerer M, Bailer RT, Enama MF, Moodie Z, et al. Phase I safety and immunogenicity evaluation of a multiclade HIV-I candidate vaccine delivered by a replicon-defective recombinant adenovirus vector. J Infect Dis 2006; 194: 1638-49.
92. Berenesi K, Guyali Z, Gonezol E, Pincus S, Cox WI, Michelson S, et al. A Canarypox vectorexpressing cytomegalous (CMV) phosphoprotien 65 induces long-lasting cytotoxic T-cell responses in human CMV-seronegative subjects. Infect Dis 2001; 183: 1171-9.
93. + T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 2012; 109: E3503-12.
94. HogenEsch H. Mechanisms of stimulation of immune response by aluminium adjuvants. Vaccine 2002; 20: 534-9.
95. Yoo JY, Kim JM, Seo KS, Jeong YK, Lee HB, Khang G. Characterization of degradation behavior for PLGA in various pH condition by simple liquid chromatography method. Biomed Mater Eng 2005; 15: 279-88.
96. Ray A, Shakya A, Kumar D, Ray BK. Overexpression of serum amyloid A-activating factor 1 Inhibits cell proliferation by the induction of cyclin-dependent protein kinase Inhibitor p21WAF-1/Cip-1/Sdi-1 Expression. J Immunol 2004; 172: 5006-15.
97. Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007; 121: 216-26.
98. Hamilton JA, Byrne R, Whitty GJ. Particulate adjuvants can induce macrophage survival, DNA synthesis, and a synergistic proliferative response to GM-CSF and CSF-Leukoc 1. Biol 2000; 67: 226-32.
99. Odumosu O, Nicholas D, Payne K, Langridge W. Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function. Vaccine 2011; 29: 8451-8.
100. Yamamoto M, Kiyono H, Kweon MN, Yamamoto S, Fujihashi K, Kurazono H, et al. Enterotoxin adjuvants have direct effects on t cells and antigen-presenting cells that result in either interleukin-4-dependent or-independent immune responses. J Infect Dis 2000; 182: 180-90.
101. Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol 2009; 87: 371-6.
102. Warren HS, Chedid LA. Future prospects for vaccine adjuvants. Crit Rev Immunol 1986; 4: 369-85.
103. Allison AC, Byans NE. Immunological adjuvants. Desirable properties and side effects. Med Immunol 1991; 28: 279-84.
104. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity 2005; 38: 473-85.
105. Antonelli LR, Gigliotti Rothfuchs A, Goncalves R, Roffe E, Cheever AW, Bafica A, et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest 2010; 120: 1674-82.
106. Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26: 6630-8.
107. Goldenthal KL, Covagnaro JA, Alving CR, Vogel FR. Safety evaluation of vaccine. Development Working Group. AIDS Res Hum Retrovirus 1993; 9: 545-9.
108. Morein B, Lövgren K, Höglund S. Immunostimulating complex (ISCOM). In: Gregoriadis G, Allison AC, Poste G, editors. Immunological adyuvants and vaccines. New York: Plenum Publishing Corporation; 1989. p. 153-61.
109. Jennings R, Simms JR, Health AW. Adjuvants and delivery systems for viral vaccines. Mechanisms and potentials in modulations of the immune response to vaccine antigens. Dev Biol 1998; 92: 19-28.
110. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000; 106: 124-34.
111. Heit A, Maurer T, Hochrein H, Bauer S, Huster KM, Busch DH, et al. Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J Immunol 2003; 170: 2802-5.
112. O'Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant-The long and winding road. Drug Discov Today 2009; 14: 541-51.